Vanda Pharmaceuticals Inc.
No SEC Form 4 filings for $VNDA in the last 30 days.
See all $VNDA insider activity →Vanda Pharmaceuticals said the FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in Q1 2026, and it plans a commercial launch in the second half of 2026. U.S. data exclusivity runs to Feb 20, 2031, with patents to May 31, 2044. Vanda reported Q2 net product sales of $50.5M and expects Phase III readouts before year-end 2026.
Vanda Pharmaceuticals (VNDA) said its motion sickness drug Nereus is now commercially available across the U.S., after FDA approval in December for preventing vomiting in adults. Vanda estimates motion sickness affects 25% to 30% of adults. Nereus is offered via direct-to-consumer and retail pharmacies, with a $85 cash-pay dose versus a $255 list price. VNDA shares rose about 4% after hours.
Vanda Pharmaceuticals (VNDA) reported weaker Q2 results, with revenue down 18% to $51m versus analyst estimates. Statutory loss was $1.04 per share, 77% worse than expected. Four analysts cut the consensus 12-month price target 12% to $12.44 and lowered revenue forecasts, while 2026 revenue consensus is $253.5m.
Over the past 7 days, alphai's AI scored 2 news stories mentioning VNDA (Vanda Pharmaceuticals Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent VNDA coverage spans earnings, regulation and technology.
The article is a forward-looking catalyst mix for VNDA: an FDA-approved product launch window plus a long patent runway and multiple late-stage milestones.
Commercial availability of Nereus after FDA approval is a near-term demand and revenue catalyst, supporting bullish sentiment and potential follow-through after-hours.
Earnings disappointment is reinforced by analyst downgrades, with revenue expectations lowered and losses expected to worsen near term.
Near-term sentiment hinges on whether BYSANTI launch execution and NEREUS confirmatory/regulatory timelines offset Hetlioz erosion and early DTC stocking uncertainty.
The 8-K provides fresh operating metrics, cash runway commentary, and multiple near-term regulatory and clinical catalysts that can re-rate VNDA’s risk/reward.
alphai scores every news story that mentions VNDA with an AI model for sentiment and relevance, and aggregates insider trades from Vanda Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vanda Pharmaceuticals said the FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in Q1 2026, and it plans a commercial launch in the second half of 2026. U.S. data exclusivity runs to Feb 20, 2031, with patents to May 31, 2044. Vanda reported Q2 net product sales of $50.5M and expects Phase III readouts before year-end 2026.
6 min readVanda Pharmaceuticals (VNDA) said its motion sickness drug Nereus is now commercially available across the U.S., after FDA approval in December for preventing vomiting in adults. Vanda estimates motion sickness affects 25% to 30% of adults. Nereus is offered via direct-to-consumer and retail pharmacies, with a $85 cash-pay dose versus a $255 list price. VNDA shares rose about 4% after hours.
3 min readVanda Pharmaceuticals (VNDA) reported weaker Q2 results, with revenue down 18% to $51m versus analyst estimates. Statutory loss was $1.04 per share, 77% worse than expected. Four analysts cut the consensus 12-month price target 12% to $12.44 and lowered revenue forecasts, while 2026 revenue consensus is $253.5m.
5 min readVanda Pharmaceuticals reported Q2 2026 drivers on its earnings call. Fanapt prescriptions rose 31% vs Q2 2025, while Hetlioz revenue fell 66% due to generic competition and a $7M shipment timing delay. Management cited higher operating expenses from four Phase 3 programs. It expects 2026 revenue growth of 23% at the midpoint, dependent on BYSANTI and NEREUS launch, and said cash should fund operations through end-2027.
6 min readVanda Pharmaceuticals Inc. (VNDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vnda8-k852026exhibit991.htm EX-99.1 Document Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results • Fanapt ® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% • Full-year 2026 total revenue guidance o
6 min readVanda Pharmaceuticals Inc. (Nasdaq: VNDA) said it will report second-quarter 2026 financial results on Aug. 5, 2026 after market close. The company plans a 4:30 PM ET conference call and webcast, with a replay available from 8:30 PM ET Aug. 5 through Aug. 12. Investors can access materials via Vanda’s website.
1 min readVanda Pharmaceuticals (VNDA) said the EMA Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation for its investigational monoclonal antibody imsidolimab for generalized pustular psoriasis. The company noted the FDA is reviewing its BLA with a target action date of Dec. 12, 2026. VNDA shares closed at $5.45.
3 min readVanda Pharmaceuticals (Nasdaq: VNDA) said the EMA Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation for imsidolimab for generalized pustular psoriasis (GPP). Vanda said this is the first EU orphan designation for a GPP treatment. The company also noted its FDA GPP BLA is under review with a Dec. 12, 2026 target action date.
3 min readThe FDA granted Vanda Pharmaceuticals’ VCA-894A therapy a rare pediatric disease designation for CMT2S, a rare inherited neurological disorder. The designation covers a pediatric population from birth to age 18 and targets a specific genetic variant found in an early-diagnosed patient. The status may support a priority review voucher if the therapy is approved, subject to FDA eligibility.
3 min readVanda Pharmaceuticals (Nasdaq: VNDA) said the FDA granted Rare Pediatric Disease Designation to VCA-894A, its investigational antisense oligonucleotide for Charcot-Marie-Tooth disease type 2S (CMT2S). The designation is for a pediatric-primarily serious/life-threatening condition and may support a future Rare Pediatric Disease Priority Review Voucher eligibility. VCA-894A targets an IGHMBP2 splice-site variant.
2 min read
